Another Superbug Killer Drug In The Making....
Torezolid, the company's most-advanced product candidate, is undergoing a phase III trial in oral dosage form for the treatment of ABSSSI (acute bacterial skin and skin structure infections). Trius acquired worldwide rights to Torezolid outside of Korea, from Dong-A Pharmaceutical Co., Ltd., in January 2007. The company also has a strategic collaboration with Bayer Pharma AG to develop and commercialize Torezolid in Asia-Pacific and emerging markets. Under the agreement inked today (July 27), Bayer will pay Trius $25 million upfront and will support about 25% of the future development costs of Torezolid required for global approval in ABSSSI and pneumonia. In addition, Trius is eligible to receive up to $69 million upon the achievement of certain development, regulatory and commercial milestones and will receive double-digit royalties on net sales of Torezolid in the licensed territory.
